AWG Member News
-
Innoviva to Acquire Entasis Therapeutics
Innoviva to acquire all outstanding shares of Entasis it does not already own for $2.20 per share in cash Price per share in cash represents a 50% premium to Entasis’ closing price of $1.47 per share on January 31, 2022 , the last date before Innoviva’s original bid became public... Read more
-
SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference
JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, President and Chief Executive Officer of SCYNEXIS, will present in person at the upcoming H.C. Wainwright Global Investment... Read more
-
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
WALTHAM, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the company presented data highlights from its pivotal... Read more
-
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief...... Read more
-
Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the... Read more
-
Iterum Therapeutics Reports First Quarter 2022 Financial Results
... Read more
-
CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time... The post CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update appeared first on CorMedix | Prevention of cardiac, renal and infectious diseases.... Read more
-
CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES
Berkeley Heights, NJ – May 12, 2022 – CorMedix Inc. (Nasdaq: CRMD),... The post CORMEDIX INC. ANNOUNCES LEADERSHIP UPDATES AND OPERATIONAL CHANGES appeared first on CorMedix | Prevention of cardiac, renal and infectious diseases.... Read more
-
SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update
JERSEY CITY, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended on March 31, 2022.... Read more
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31,... Read more
-
Iterum Therapeutics Provides Regulatory Update
... Read more
-
Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update
... Read more
-
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
JERSEY CITY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced the presentation of new positive outcomes in patients with refractory vulvovaginal candidiasis (VVC) treated with oral ibrexafungerp from the ongoing Phase 3... Read more
-
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026-... Read more
-
SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, May 12, 2022 to provide a... Read more
-
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it agreed to an extension of its exclusive agreement with subsidiaries of Merck... Read more
-
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE...... Read more
-
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE...... Read more
-
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting
Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25 years Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in... Read more
-
CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12
Berkeley Heights, NJ – May 3, 2022 – CorMedix Inc. (Nasdaq: CRMD),... The post CORMEDIX INC. TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON MAY 12 appeared first on CorMedix | Prevention of cardiac, renal and infectious diseases.... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on April 29, 2022, the...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on April 29, 2022, the...... Read more
-
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on April 29, 2022, the...... Read more
-
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights... Read more
-
Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update
... Read more
-
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases
JERSEY CITY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced several poster presentations highlighting details from interim analyses of data from its ongoing Phase 3 FURI and CARES studies investigating the... Read more
-
Entasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business Update
Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conference SUL-DUR NDA submission on track for mid-2022 Zoliflodacin Phase 3 trial progressing; enrollment completion now anticipated in 2023 WALTHAM, Mass.... Read more
-
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants were sold at a public offering price of $3.00 per share and accompanying warrants, and... Read more
-
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022. The audio webcast can be... Read more
-
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022. The audio webcast can be... Read more